aTyr Pharma Reports $7.43 Quarterly Loss

The biotech company reported its third-quarter results and outlined its cash runway and Phase 3 plans for efzofitimod.

Updated on Nov. 7, 2026 in Corporate Finance

aTyr Pharma Reports $7.43 Quarterly Loss

aTyr Pharma reported a GAAP loss of $7.43 per share for the quarter ended Sept. 30, 2026, and held $50.3 million in cash, cash equivalents, restricted cash and available-for-sale investments at that date. The company said its current resources are expected to fund operations into late 2028.

Why it matters

The quarter's loss and cash position frame how long aTyr Pharma can continue developing efzofitimod without raising additional capital. The company said it plans to prioritize strategic partnerships to advance the Phase 3 study.

aTyr Pharma reported a GAAP loss of $7.43 per share and $50.3 million in cash and investments at Sept. 30, 2026. The filing does not provide a prior-period comparison, and the timing and terms of any future financing or partnership remain unannounced.

The players

aTyr Pharma

A clinical-stage biotechnology company developing efzofitimod for pulmonary sarcoidosis, whose stock trades on the Nasdaq exchange.

Food and Drug Administration

The U.S. federal agency responsible for regulating drugs and biologics, which aligned with aTyr Pharma on the Phase 3 study protocol.

The details

aTyr Pharma reached alignment with the Food and Drug Administration on a Phase 3 study protocol for efzofitimod targeting patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. Study-related activities for the Phase 3 study have begun.

Sept. 30, 2026: Quarter ended, with $50.3 million in cash and investments reported.
Q3 2026: Company reported a GAAP loss of $7.43 per share.
Late 2028: Current resources are expected to fund operations.

Market Dynamics

The FDA protocol alignment that aTyr Pharma reached for efzofitimod is the procedural step that typically precedes Phase 3 enrollment for sarcoidosis drugs. Companies in this stage often rely on partnerships or financing to fund trials that extend beyond their current cash runway.

Investors holding aTyr Pharma shares face a company whose current resources reach into late 2028 but whose Phase 3 study may require additional funding or partnerships. A $7.43 per-share GAAP loss in a single quarter underscores the financing risk that shareholders would bear if new capital is raised.

The takeaway

aTyr Pharma's cash position supports operations into late 2028, but the company's pursuit of a Phase 3 study and its reliance on partnerships mean investors should watch for financing announcements. Tracking quarterly cash burn against the stated runway offers a practical way to assess the company's funding position.